Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Innovative Clinical Trial Design: Commercial vs Open-Source Software? Why Not Both?

In the ever-changing field of clinical trial design, there is often a need to evaluate design options quickly and efficiently. But when it comes to evaluating options, which is better: commercial or open-source software? And does it need to be a question of either-or?

Read full article

Perspectives on Enquiry and Evidence

April 8, 2022

Robust Trial Design Under Treatment and Enrollment Uncertainty

The planning and optimization of a clinical trial is beset by uncertainties: knowledge of treatment effects, the...

Read article

March 23, 2022

How to Use Historical Data to Mitigate Clinical Trial Risk

For over a decade, the number one reason cited for trial discontinuity has been challenges associated with recruitment...

Read article

January 11, 2021

COVID-19 Trial Tracker Updates (January 11)

In April 2020, Cytel launched an open-access global COVID-19 Clinical Trial Tracker to help facilitate greater...

Read article

June 9, 2020

Melinda Gates, on COVID-19 and Drug Development in Emerging Economies

Trevor Mundel leads the Bill & Melinda Gates Foundation’s efforts to develop high-impact interventions against the...

Read article

September 5, 2018

Podcast: Enhancing Patient Enrollment Forecasting with EnForeSys 2.0

EnForeSys is Cytel’s tool for patient recruitment planning. We have discussed on the blog recently with Tufts...

Read article

April 13, 2018

Exploring Challenges of Clinical Trial Operations Part 2 with Ken Getz

We return to our discussion with Ken Getz of the Tufts CSDD for part 2 of our blog post on key challenges in clinical...

Read article

April 5, 2018

Ken Getz: Exploring Challenges of Clinical Trial Operations

Photo by J. Kelly Brito on Unsplash Research on clinical trial enrollment makes for sobering reading, characterized by...

Read article

July 6, 2017

When Biostatisticians Disagree About Ethics

By Esha Senchaudhuri The ethical benefits of adaptive clinical trials have been widely acclaimed: higher prospects for...

Read article

December 2, 2016

Innovative Phase 3 Adaptive Enrichment Design in Oncology

At a recent Pfizer/ Cytel seminar on rare disease and oncology development, Cytel’s Lingyun Liu presented innovative...

Read article

September 7, 2016

Overcoming challenges of 'Less Well Understood' Adaptive Designs

In the 2010 draft FDA ‘Guidance for Industry on Adaptive Design Clinical Trials for Drugs and Biologics', the agency...

Read article

June 4, 2015

Patient Recruitment Feasibility: Would you bet $12 million dollars on it?

Two insightful papers from Applied Clinical Trials should be of interest to many clinical trial planners. The first by...

Read article

April 13, 2015

New Cytel Whitepaper: Monte Carlo Simulations for Patient Recruitment

Cytel has published a new whitepaper on Monte Carlo Simulations for Patient Recruitment, which illustrates how a...

Read article

April 2, 2015

Monte Carlo Simulations II: Reassessing Strategic Options During an Interim Look

Midway through a trial is a terrible time to realize that you need a new strategy to complete the study. Sadly, it is...

Read article

March 12, 2015

Monte Carlo Simulations for Patient Enrollment: A Presentation

Recently, we published an interview with Chris Conklin, the Director of the Center for Feasibility Excellence at...

Read article

February 12, 2015

Data-Driven Trial Planning: An Interview with Pfizer's Chris Conklin

Data driven decision-making can ensure that every feasibility team achieves its enrollment milestones. By transforming...

Read article

February 5, 2015

3 Key Trends in Clinical Trial Enrollment Forecasting

Every clinical trial requires some manner of trial forecasting, normally for feasibility and patient enrollment....

Read article

January 27, 2015

How to Take Control of Your Enrollment Woes

Last week we released an infographic on why Phase 3 trials fail. The numbers, while eye-opening, did not capture a...

Read article